Display options
Cite
Rao TR, Usha PR, Naidu MU, et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 2003;64(9):685-96doi: 10.1016/j.curtheres.2003.09.014.
Rao, T. R., Usha, P. R., Naidu, M. U., Gogtay, J. A., & Meena, M. (2003). Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Current therapeutic research, clinical and experimental, 64(9), 685-96. https://doi.org/10.1016/j.curtheres.2003.09.014
Rao, Takallapalli Ramesh Kumar, et al. "Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures." Current therapeutic research, clinical and experimental vol. 64,9 (2003): 685-96. doi: https://doi.org/10.1016/j.curtheres.2003.09.014
Rao TR, Usha PR, Naidu MU, Gogtay JA, Meena M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 2003 Nov;64(9):685-96. doi: 10.1016/j.curtheres.2003.09.014. PMID: 24944416; PMCID: PMC4053054.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2003 Nov;64(9):685-96. doi: 10.1016/j.curtheres.2003.09.014.

Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures.

Current therapeutic research, clinical and experimental

Takallapalli Ramesh Kumar Rao, P Rani Usha, M U R Naidu, J A Gogtay, Matthew Meena

Affiliations

  1. Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, India.
  2. Medical and Research Department, Cipla Ltd., Mumbai, India.

PMID: 24944416 PMCID: PMC4053054 DOI: 10.1016/j.curtheres.2003.09.014

Abstract

BACKGROUND: The role of platelets in acute cardiovascular atherothrombotic events has been well established and attention has focused on platelet inhibition therapy. Clopidogrel is a novel thienopyridine inhibitor of adenosine diphosphate-induced platelet activation. Recent studies have shown that in the setting of coronary angioplasty/stenting, a loading dose of 300 mg followed by 75 mg once daily is required for optimum benefit.

OBJECTIVE: This study assessed the bioequivalence and tolerability of 2 oral formulations of clopidogrel 75-mg tablets.

METHODS: This 10-day, open-label, randomized, parallel-group, comparative bioequivalence and tolerability study was carried out in the Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences (Hyderabad, India). Young healthy male volunteers were enrolled. Subjects were randomized to receive one of two 75-mg tablet formulations of clopidogrel (Clopivas(®) [test formulation] or Plavix(®) [reference formulation]). Subjects first received a 300-mg loading dose (four 75-mg tablets) on day 1, followed by 75 mg (1 tablet) at 8:00 AM daily for the next 6 days. Inhibition of platelet aggregation, which is the pharmacologic basis for the therapeutic efficacy of antiplatelet agents, and the effect on bleeding time were used as the pharmacodynamic assessment criteria. Pharmacodynamic variables included mean of maximum activity of percentage of inhibition of platelet aggregation (Emax), mean time to reach Emax (tmax), and mean area under the activity-time curve from time 0 to 168 hours (AUC0-168). Tolerability assessments included blood pressure and heart rate measurements before and at regular intervals (every hour for 12 hours and then at 24 hours) over a 24-hour period after drug administration. Clinical tolerability was assessed using adverse effects, platelet count (assessed on days 3, 6, and 10 after first-dose administration), and neutrophil count (assessed on day 10 after first-dose administration).

RESULTS: Twenty subjects were enrolled (mean [SD] age, 26.5 [2.9] years [range, 22-32 years]). Emax, tmax, and AUC0-168 were similar between the 2 groups, as was bleeding time. The 90% CIs were within the bioequivalence acceptance range of 80% to 125%. One subject (10%) in the Plavix group experienced mild headache; no serious adverse effects were reported, and none of the subjects dropped out due to an adverse effect. Platelet and neutrophil counts were found to be within normal limits.

CONCLUSIONS: In this study of healthy male volunteers, the 2 tablet preparations of clopidogrel showed bioequivalence. However, the sample size was smaller than that generally recommended for a bioequivalence study, and additional studies with larger sample sizes are needed.

Keywords: ADP-receptor antagonist; bioequivalence; bleeding time; clopidogrel; platelet aggregation

References

  1. Drugs. 1995 Jul;50(1):7-28 - PubMed
  2. Semin Thromb Hemost. 1999;25 Suppl 2:3-8 - PubMed
  3. Lancet. 1996 Nov 16;348(9038):1329-39 - PubMed
  4. BMJ. 1994 Jan 8;308(6921):81-106 - PubMed
  5. Thromb Haemost. 1988 Apr 8;59(2):225-30 - PubMed
  6. Arterioscler Thromb. 1992 Apr;12(4):430-6 - PubMed
  7. Med Res Rev. 1996 Mar;16(2):159-79 - PubMed
  8. N Engl J Med. 1992 Jan 23;326(4):242-50 - PubMed
  9. Semin Thromb Hemost. 1999;25 Suppl 2:9-14 - PubMed
  10. Circulation. 2000 Aug 8;102(6):624-9 - PubMed
  11. N Engl J Med. 1992 Jan 30;326(5):310-8 - PubMed
  12. Thromb Res. 1979;14(6):901-14 - PubMed
  13. N Engl J Med. 2001 Aug 16;345(7):494-502 - PubMed
  14. J Clin Invest. 1991 Nov;88(5):1690-6 - PubMed
  15. Semin Thromb Hemost. 1999;25 Suppl 2:15-9 - PubMed

Publication Types